compounded microdose glp 1 GLP-1 Injections Microdosing - IV Total Health

Imbruvica (ibrutinib) Disease area(s): Oncology/hematology Manufacturer(s): AbbVie/Johnson & Johnson 2024 Sales (USD): $6.39 billion Why it sold so well: In 2024, Johnson & Johnson saw a 7% decline in global revenues of Imbruvica, primarily due to decreased demand and lower market share in the US, as well as reduced collaboration revenues internationally

Biochemistry 41 , 84558463 (2002)

They are distinct medications with different mechanisms and outcomes

Unlike other growth hormone secretagogues, it appears to selectively promote growth hormone release without markedly affecting prolactin, TSH, ACTH, LH, or cortisol